Ponesimod-d7

• CAT Number: I040340
• Molecular Formula: C23H18D7ClN2O4S
• Molecular Weight: 468.02
• Purity: ≥95%
• Synonyms: (5Z)-5-[[3-chloro-4-[(2R)-2,3-dihydroxypropoxy]phenyl]methylidene]-2-propylimino-3-[2,3,4,5-tetradeuterio-6-(trideuteriomethyl)phenyl]-1,3-thiazolidin-4-one
• InChI: InChI=1S/C23H25ClN2O4S/c1-3-10-25-23-26(19-7-5-4-6-15(19)2)22(29)21(31-23)12-16-8-9-20(18(24)11-16)30-14-17(28)13-27/h4-9,11-12,17,27-28H,3,10,13-14H2,1-2H3/b21-12-,25-23?/t17-/m1/s1/i2D3,4D,5D,6D,7D
• InChIKey: LPAUOXUZGSBGDU-OUJBTHLMSA-N
• SMILES: [2H]C1=C(C(=C(C(=C1[2H])C([2H])([2H])[2H])N2C(=O)/C(=C/C3=CC(=C(C=C3)OC[C@@H](CO)O)Cl)/SC2=NCCC)[2H])[2H]

Ponesimod-d7(CAT: I040340) is a stable isotope-labeled analog of Ponesimod, incorporating seven deuterium atoms for enhanced performance in mass spectrometry-based analytical applications. It is primarily utilized as an internal standard in pharmacokinetic, ADME, and bioavailability studies, allowing for precise quantification and metabolic tracking of Ponesimod in biological samples. As a selective S1P₁ receptor modulator, Ponesimod-d7 supports research into immune cell trafficking and autoimmune disease mechanisms, particularly in the context of multiple sclerosis. Its isotopic labeling ensures reliable differentiation from the non-labeled compound, aiding in the evaluation of drug behavior, stability, and therapeutic monitoring under experimental and clinical research conditions.